CARSGEN
THERAPEUTICS

CARsgen Therapeutics Holdings Limited
科濟藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT
SHARE REPURCHASE BY THE COMPANY

This announcement is made by CARsgen Therapeutics Holdings Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**" or "**CARsgen**") on a voluntary basis.

As approved by the shareholders at the annual general meeting held on May 22, 2026, the Company was granted a mandate to repurchase up to 10% of the total issued shares of the Company (the "**Shares**") (excluding any treasury shares) as at the date of passing of such ordinary resolution, being a maximum of 57,096,024 Shares (the "**2026 Share Repurchase Mandate**").

The Company is pleased to announce that a share repurchase plan has been approved by the board of directors of the Company (the "**Board**") to repurchase Shares not exceeding 30,124,699 Shares, representing approximately 5% of the total issued Shares as of May 31, 2026, in the open market from June 25, 2026 to the conclusion of the next annual general meeting of the Company, pursuant to the 2026 Share Repurchase Mandate.

The funds to be used for the share repurchases come from non-IPO raised funds, which include, among others, business development (BD) income, interest income, and other subsidy. The Company shall conduct the share repurchases by exercising its powers under the 2026 Share Repurchase Mandate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and all applicable laws and regulations to which the Company is subject.

Shareholders and potential investors should note that the implementation of the on-market share repurchases by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity, or price of any share repurchases or whether the Company will make any share repurchases at all.

Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, June 26, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.